Navigation Links
Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
Date:5/17/2011

or RAPAFLO(R) 4 mg, 13.3 percent for RAPAFLO(R) 8 mg, and 1.9 percent for placebo.

Study Design

The double-blind, 12-week, placebo-controlled Phase 2 study evaluated the safety and efficacy of RAPAFLO(R) in patients with moderate to severe non-bacterial CP/CPPS who previously had not received alpha-blockers for the condition.  Patients with National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total score >/=15 (moderate to severe), NIH-CPSI pain score >/=8 (mild to moderate), and pelvic pain for >/=3 months before screening were randomized to RAPAFLO(R) 4 mg or 8 mg per day, or placebo. The primary measure of efficacy was improvement in the NIH-CPSI total score. Of 151 participants, 76.2 percent completed the study. The median age of patients was 48.2 years; 80.1 percent had experienced pain for at least one year.

Secondary end points evaluated were: safety; change from baseline in NIH-CPSI pain, urinary, and quality of life scores; and change from baseline in Medical Outcomes Study Short Form 12 (SF-12) physical and mental component scores. Additional secondary end points were percentages of participants who had a sufficiently significant decrease in total score (NIH-CPSI responders) and of those who indicated "markedly improved" or "moderately improved" on the global response assessment (GRA) scale (GRA responders).

About RAPAFLO(R) (silodosin)

RAPAFLO(R) was first approved by the FDA two years ago for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO(R) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(R) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alp
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Watson Confirms Renvela® Patent Challenge
2. Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
3. Watsons GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
4. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
5. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
6. Vanda Pharmaceuticals Reports First Quarter 2011 Results
7. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
8. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to a new market report published by ... was valued at USD 3,754.6 million in 2012 and is ... a CAGR of 5.9% from 2013 to 2019. , Nearly ... afflicted by bone and joint disorders, and this number is ... and will continue to increase the demand for orthobiologics. Other ...
(Date:8/29/2014)... PA (PRWEB) August 29, 2014 Pittcon ... Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have ... on September 5, 2014. JASIS , Asia’s largest ... 3-5, 2014, in Makuhari Messe, Japan. , The ... Tools for Bioanalysis from Single Molecules to Single Cells” ...
(Date:8/29/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the six months ended June 30, 2014. ... dollars and presented under International Financial Reporting Standards ... , Announced top-line results related to the ... subjects enrolled in the Phase 2 iDEAL Study ...
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
Breaking Biology Technology:Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Mass., Oct. 20 Genstruct Inc., a systems,biology ... to better understand large-scale biology, announced today that,it ... of Engineering. In his,new role, Dr. Ray will ... Genstruct technology platform, customer platforms and the company,s,IT ...
... Senomyx, Inc.,(Nasdaq: SNMX ) will release its third ... the opening of the U.S. financial,markets. The Company will ... that will provide a business update and a review ... 11:00 a.m. Eastern Time (8:00 a.m.,Pacific Time)., To ...
... as President , ... San Diego/Phoenix (PRWEB) October ... based on the products of newborn dermal fibroblasts, today announced the ... growing medical aesthetic industries based on Histogen,s core technology. , , ...
Cached Biology Technology:Genstruct Expands Team with New VP of Engineering 2Genstruct Expands Team with New VP of Engineering 3SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 2Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 3Histogen Aesthetics is Created to Address Growing Medical Aesthetics Market 4
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
(Date:8/27/2014)... single fungal cell or bacterial colony exerts on a plant ... role in setting up some of the most fundamental symbiotic ... much of a stretch to say that plants may have ... the touch of beneficial fungi, according to a new study ... University of Wisconsin-Madison. , "Many people have studied how ...
(Date:8/27/2014)... short-faced bears, giant ground sloths, saber-toothed cats and American ... ago at the end of the Pleistocene period. The ... by scientists who, until recently, could only speculate as ... Santa Barbara,s James Kennett, professor emeritus in the Department ... Earth played a major role in the extinction. Their ...
Breaking Biology News(10 mins):Paleontology: Oldest representative of a weird arthropod group 2A touching story: The ancient conversation between plants, fungi and bacteria 2A touching story: The ancient conversation between plants, fungi and bacteria 3Nanodiamonds are forever 2Nanodiamonds are forever 3
... that some brain tumours in larvae of the fruit fly ... cells to grow. The removal of some of these genes ... are crucial for tumour development. The study, headed by ICREA ... Science . One of the characteristics of ...
... mankind,s migration from Africa to the New World, and the ... international study that for the first time will dig deep ... a mile) down under 300 meters (about a fifth of ... researchers will look back in time to collect a massive ...
... University of Exeter have developed a new approach to ... up the process of finding vaccines. Dr Andrea ... the university,s Cornwall Campus, has pioneered a simple screen ... gene structures of pathogenic* bacteria. The screen allows ...
Cached Biology News:Some brain tumors mimic the genetic program of germline cells 2Back to the dead (sea, that is) 2Finding new ways to tackle environmental diseases 2
... formulated for non-denaturing polyacrylamide and agarose gel ... solution contains a bromophenol blue tracking dye ... sample loading. EDTA has been included to ... SDS has been added to help dissociate ...
... Antibody Description: ... antibody. Detects 70 kDa YAP from ... and immunohistochemistry. ... Storage: -20C ...
...
... M-PER Mammalian Protein Extraction ... cell lysis solution that means ... and no sonication! With M-PER ... just five minutes at room ...
Biology Products: